| 0.0001 -0.001 (-85.71%) | 12-22 14:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0  |
MA(250) : | 0.19 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 45.5 |
| RSI | RSI(14): 59.9 | |||
| 52-week | High : | 1.45 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GNCA ] has closed below upper band by 15.9%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Thu, 19 Feb 2026
GNCA stock at $0.00 on 19 Feb 2026: market closed, recovery signals weak - Meyka
Fri, 13 Feb 2026
Pre-Market Top Loser: GNCA Genocea Biosciences (NASDAQ) 13 Feb 2026: liquidity flag - Meyka
Thu, 05 Feb 2026
After Hours Top Loser 05 Feb 2026: GNCA Genocea NASDAQ at $0.0001, see liquidity - Meyka
Fri, 23 Jan 2026
GNCA (Genocea Biosciences, Inc.) NASDAQ down 97.44% pre-market 23 Jan 2026: Key signals for traders - Meyka
Wed, 21 Jan 2026
GNCA stock falls to $0.0001 on NASDAQ 20 Jan 2026: catalysts and outlook - Meyka
Fri, 16 Jan 2026
GNCA $0.0001 Genocea (NASDAQ) 15 Jan 2026: Intraday top loser, liquidity alert - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 5.411e+007 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.567e+007 |
| EPS Est Next Qtrly | -0.38 |
| EPS Est This Year | -1.92 |
| EPS Est Next Year | -1.12 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 958.8 % |
| Return on Equity (ttm) | -57.6 % |
| Qtrly Rev. Growth | 1.91e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -328.62 |
| EBITDA (p.s.) | 1.025e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 1.64e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-05-21 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|